https://www.selleckchem.com/products/sm-102.html
Diabetes is one of the most urgent healthcare challenges that we are currently facing, and there is a growing need for medications which can manage the condition on a long-term basis. Researchers at Stockholm University working with startup Atrogi AB have developed a novel approach which targets the β2 adrenergic receptors, circumventing the failing insulin signaling pathway. This unique way of addressing the problem potentially opens the way to a new class of diabetes medications.We tested pre-pandemic (2015-2019) plasma samples from 14
Like
Comment
Share
